ESMO 2026 | INTerpath-001: intismeran autogene plus pembrolizumab in resected melanoma
Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, Sydney, Australia, discusses results from the Phase III INTerpath-001 study (NCT05933577), which evaluated intismeran autogene, an mRNA-based individualized neoantigen therapy, and pembrolizumab versus pembrolizumab alone as adjuvant treatment in resected stage IIB-IV melanoma. The combination significantly improved recurrence-free and distant metastasis-free survival, with consistent benefit across subgroups and a generally well-tolerated safety profile. These findings set a new benchmark for adjuvant melanoma treatment and represent an advance in personalized medicine. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
